Saturday 17 October 2026
Export GERN’s income statement to Excel — free account
Geron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.
1.17
0.06
−4.88%
Follow GERN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (28.28%) | (27.07%) | (32.99%) | (29.57%) | ||
| (12.59%) | (12.28%) | (14.34%) | (15.80%) | ||
ROIC |
(89.85%) | (93.28%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(16.21%) | (15.80%) | (20.39%) | (18.36%) | |
Average Days of Receivables |
95.47 | 82.07 | 77.86 | 74.94 | |
Free Cash Flow per Share |
(0.17) | (0.19) | (0.17) | (0.20) | |
Free Cash Flow |
(114.76) | (126.30) | (111.09) | (132.82) | |
Capital Expenditures |
(0.39) | (0.33) | (0.05) | 0.09 | |
| Other line items | |||||
Cash ROIC |
(17.89%) | (19.04%) | (15.75%) | (17.70%) | |
Accounts Receivable Turnover |
4.41 | 5.02 | 4.71 | 5.41 | |
Accounts Payable Turnover |
1.56 | 0.50 | 0.48 | 0.34 | |
Inventory Turnover |
0.14 | 0.06 | 0.06 | 0.07 | |
Average Days of Payables |
241.99 | 887.56 | 865.92 | 960.57 | |
Days of Inventory on Hand |
3,396.99 | 9,300.28 | 8,972.00 | 8,249.42 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
35.00% | 36.36% | 38.85% | 44.34% | |
Selling, General and Administrative Expense of Revenue |
75.75% | 78.86% | 86.61% | 87.76% | |
Share Based Compensation of Revenue |
10.96% | 12.36% | 14.55% | 15.14% | |
Interest Coverage |
(1.71) | (1.64) | (2.10) | (1.85) | |
Operating CF/Net income |
1.69 | 1.87 | 1.33 | 1.66 | |
Depreciation/Fixed assets |
(2.17) | (3.45) | (5.26) | (11.15) | |
Capex/Depreciation |
0.16 | 0.10 | 0.01 | (0.01) | |
Revenue per Share |
0.31 | 0.29 | 0.28 | 0.27 | |
Operating CF per Share |
(0.17) | (0.19) | (0.17) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates